ArticleJCO precision oncology2019

Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay.

Katherine Clifton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.